Recent Updates
Recently added Catalysts
TWST Positive Sentiment

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Key Takeaway: Twist Bioscience Corporation has announced a proposed public offering of $250 million in common stock. The company also plans to grant underwriters a 30-day option to purchase an additional $37.5 million in shares. This move aims to bolster its financial resources and support future growth initiatives.

Market Sentiment Analysis

POSITIVE FACTORS

  • Twist Bioscience is raising significant capital through a public offering.
  • The offering may enhance the company's financial position and growth potential.
  • The underwriters have the option to purchase additional shares, indicating strong interest.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by

Frequently Asked Questions

What is the amount of the public offering by Twist Bioscience?

Twist Bioscience announced a public offering of $250 million in common stock.

Is there an option for underwriters in the offering?

Yes, underwriters have a 30-day option to purchase an additional $37.5 million in shares.

What is the purpose of the public offering?

The offering aims to enhance Twist Bioscience's financial resources and support growth.

Last updated: Aug 4, 2026